{
  "document_info": {
    "file_name": "Example Viking QAP013.01 Risk Management Final.pdf",
    "file_path": "/Users/matthewparson/Desktop/SC/Risk Management/Example Viking QAP013.01 Risk Management Final.pdf",
    "file_size_bytes": 724940,
    "uploaded_file_id": "file-U7TAxfLL8NGe4cQTrSKUJR",
    "content_hash": "45a2637b23af0c79117408aca590af18dc85f965683b9369ce51ca2bd36c6fd7",
    "file_id_cache_hit": true,
    "model": "gpt-5",
    "evaluated_at": "2025-09-25T23:39:57.119598",
    "run_id": "20250925_233957"
  },
  "evaluation_summary": {
    "total_requirements": 10,
    "compliance_score": 10.0,
    "status_counts": {
      "PASS": 1,
      "FAIL": 5,
      "FLAGGED": 4,
      "NOT_APPLICABLE": 0,
      "ERROR": 0
    },
    "total_tokens_used": 174616,
    "estimated_cost_usd": 0.8731
  },
  "requirements_results": [
    {
      "status": "FLAGGED",
      "confidence": 0.68,
      "rationale": "The SOP establishes an active system to collect and review safety-relevant information during production and post-production and integrates it into the Risk Management process. It lists multiple active and passive data sources and defines roles/responsibilities. However, it references, rather than provides, the actual Post Market Surveillance (PMS) and Complaint Handling procedures, and does not include or cite dedicated vigilance/field action procedures or specific tools/data pipelines. Acceptance criteria are partially met but key artifacts and tool/process specifics are missing.",
      "evidence": [
        "Section 5.12.1: \"Information relevant to the combination product shall be actively collected and reviewed in the production and post-production phases... This information is collected in the Post Market Surveillance and Complaint Handling Process.\"",
        "Section 5.12.2: \"Information collected and reviewed about the combination product shall entail the following considerations, at a minimum:\" including \"Information generated during production and monitoring of the production process,\" \"Information generated by the user,\" \"Information generated by the supply chain,\" \"Publicly available information,\" and \"Information related to the generally acknowledged state of the art.\"",
        "Section 5.12.3: \"The information collected shall be reviewed for possible relevance to safety, especially with respect to the following: Previously unrecognized hazards or hazardous situations are present... The overall residual risk is no longer acceptable... The generally acknowledged state of the art has changed.\"",
        "Section 5.12.4: \"If any of these conditions occur, the following activities shall be performed: The risk management file shall be reviewed... Consider the need for actions regarding combination products on the market... Provide the results of the evaluation as an input for the review of suitability of the risk management process by top management.\"",
        "Section 5.12.5: \"The results of any production and post-production evaluation(s) shall be recorded in the affected documents in the risk management file which include the risk management plan, hazards analysis, FMEAs, and risk management report.\"",
        "Section 5.2.8: \"Method(s) for obtaining and reviewing relevant product-specific production and post\u2011production information... At a minimum, data from the complaint handling process, if applicable, shall be used... Potential sources of post-production information may include, but are not limited to: Commercial & Clinical complaints (if applicable); Manufacturing and process performance data.\"",
        "Section 5.2.9: \"The risk management plan should include documentation of decisions, based on risk analysis, about what sort of post-market surveillance is appropriate... whether reactive surveillance is adequate or whether proactive studies are needed.\"",
        "Section 5.11.1.4: \"Appropriate methods to collect and review the information in the production and post-production phases have been determined and are in place.\"",
        "Section 2 (Responsibilities) \u2013 Quality Assurance Management: \"Overall responsibility for effective execution and oversight of risk management process... Overall responsibility for the Quality Management System (QMS), including the risk management process... establishing, implementing, maintaining, and reviewing the effectiveness of the risk management process.\"",
        "Section 5.3.5: \"The contents of the risk management file... shall be controlled and maintained in the document management system in accordance with QAP001, Format, Content, Approval and Issuance of Controlled Documents.\""
      ],
      "gaps": [
        "No dedicated PMS Plan document provided; PMS activities are described within the RMP framework but a standalone PMS Plan is not included.",
        "Referenced \"Post Market Surveillance and Complaint Handling Process\" is not supplied or cited with a controlled document number.",
        "No explicit vigilance/field safety corrective action or regulatory reporting procedures referenced or provided.",
        "Specific tools/data pipelines (e.g., systems for intake, triage, trending/metrics, signal detection, literature monitoring tools) are not defined.",
        "Roles for day-to-day PMS operations (beyond general RM/QMS responsibilities) are not explicitly delineated (e.g., PMS process owner, complaint unit, safety surveillance lead)."
      ],
      "recommendations": [
        "Provide or reference the controlled PMS Plan document that operationalizes 5.2.8\u20135.2.9 (including surveillance type, methods, cadence, metrics, and signal detection criteria).",
        "Attach or cross-reference the Complaint Handling SOP with document number, including intake, investigation, MDR/MIR/NCAR decision trees, and timelines.",
        "Provide or reference vigilance/field action procedures (e.g., Field Safety Corrective Action/Recall SOP and regulatory reporting SOP) to complete the P&PP system.",
        "Define and document specific tools and data pipelines (e.g., complaint database, trending dashboards, literature surveillance tools, manufacturing quality data feeds) and how data flow into the RMF.",
        "Clarify operational responsibilities for PMS (process owner, data analysis responsibilities, management review inputs) and establish review cadence and KPIs in the PMS Plan."
      ],
      "requirement_id": "ISO14971-10.1-01",
      "tokens_used": 18219
    },
    {
      "status": "FLAGGED",
      "confidence": 0.7,
      "rationale": "The SOP clearly defines routine collection of production and post-production information from the ISO 14971:2019 Clause 10.2 sources (production/process monitoring; user and maintenance/servicing; supply chain; publicly available information; state of the art). It also references use of similar products, AE databases and publications. However, explicit evidence of a periodic literature/signal review process and explicit competitor/alternative therapy monitoring cadence is not clearly stated in post-market surveillance terms within this document. The SOP relies on a separate Post Market Surveillance and Complaint Handling Process, which is not provided, and does not present concrete artifacts (supplier records, service logs, literature review logs) or a defined schedule for literature/signal review.",
      "evidence": [
        "Section 5.12.1: \"Information relevant to the combination product shall be actively collected and reviewed in the production and post-production phases... This information is collected in the Post Market Surveillance and Complaint Handling Process.\"",
        "Section 5.12.2: Lists sources to collect and review, including: \"Information generated during production and monitoring of the production process\" (5.12.2.1); \"Information generated by the user\" (5.12.2.2); \"Information generated by those accountable for the installation, use and maintenance of the combination product (as applicable)\" (5.12.2.3); \"Information generated by the supply chain\" (5.12.2.4); \"Publicly available information\" (5.12.2.5); and \"Information related to the generally acknowledged state of the art\" (5.12.2.6).",
        "Section 5.2.8: \"Method(s) for obtaining and reviewing relevant product-specific production and post\u2011production information...\" and 5.2.8.1: \"At a minimum, data from the complaint handling process... Potential sources... may include, but are not limited to: Commercial & Clinical complaints... Manufacturing and process performance data.\"",
        "Section 5.6.3.3.1: Hazard identification methods include \"Review of the same or similar combination products (internally or externally), adverse event (AE) databases, publications, and other sources.\"",
        "Section 5.7.3: Risk estimation sources include \"Published standards; Scientific or technical investigations; Field data from similar combination products already in use, including publicly available reports of incidents;... Clinical evidence;... Expert opinion.\"",
        "Section 5.12.3: Collected information is reviewed for safety relevance, including if \"The generally acknowledged state of the art has changed.\"",
        "Section 5.13.1: \"Periodic reviews of risk management documentation shall be conducted as a post market activity on an annual basis...\""
      ],
      "gaps": [
        "No explicit, documented cadence or procedure for periodic literature review and signal detection in the post-market phase within this SOP (relies on an external PMS/Complaint Handling process not provided).",
        "Competitor/alternative therapy monitoring is implied (similar products, state of the art, publications) but not explicitly defined as a routine, scheduled activity in the post-market context.",
        "No concrete expected artifact examples provided (e.g., supplier quality records, service logs, complaint database extracts, literature review logs) within this document.",
        "Servicing feedback is addressed conditionally (\"as applicable\"), but procedures/artifacts such as service/maintenance logs are not specified.",
        "Supply chain input is listed as a source, but the mechanism, frequency, and artifacts (e.g., supplier quality performance summaries) are not detailed here."
      ],
      "recommendations": [
        "Augment Section 5.12 to explicitly require and define a periodic literature and signal detection review cadence (e.g., monthly/quarterly searches of AE databases, literature databases, and regulatory safety alerts) with roles, methods, and documentation requirements.",
        "Explicitly define competitor and alternative therapy monitoring within post-market surveillance (e.g., tracking similar devices/drug-device combinations and alternative therapies, with defined sources and frequency).",
        "Reference or incorporate the Post Market Surveillance and Complaint Handling Process details for literature/signal reviews, including example logs/templates, and ensure cross-references include document numbers.",
        "Specify servicing feedback mechanisms and artifacts (e.g., service/maintenance logs, field service reports) where applicable, or state criteria when not applicable.",
        "Define supply chain information ingestion methods and artifacts (e.g., supplier scorecards, SCARs, incoming quality trends) and their review frequency.",
        "Maintain and cite example artifacts in the Risk Management File index: complaint database outputs, PMS reports, literature review logs, supplier quality records, and service logs to evidence routine ingestion from all sources."
      ],
      "requirement_id": "ISO14971-10.2-01",
      "tokens_used": 17804
    },
    {
      "status": "FAIL",
      "confidence": 0.74,
      "rationale": "The SOP defines how production and post-production information is reviewed for safety relevance and escalated back into the risk management process, including explicit triggers and requirements to update RM documents. However, required acceptance artifacts are not provided: no signal/safety review minutes, no evidence of actual updates to hazard analysis/RMP, and no CAPA records. The document references post-market surveillance and management review but does not supply the minutes or a dedicated signal management SOP. Therefore, not all acceptance criteria are satisfied.",
      "evidence": [
        "Section 5.12.1: \"Information relevant to the combination product shall be actively collected and reviewed... This information is collected in the Post Market Surveillance and Complaint Handling Process.\"",
        "Section 5.12.3: Triggers documented for safety relevance review: \"5.12.3.1. Previously unrecognized hazards or hazardous situations are present; 5.12.3.2. An estimated risk arising from a hazardous situation is present; 5.12.3.3. The overall residual risk is no longer acceptable in relation to the benefits of the intended use; 5.12.3.4. The generally acknowledged state of the art has changed\"",
        "Section 5.12.4: Required escalation and feedback actions: \"5.12.4.1. The risk management file shall be reviewed to determine if reassessment of risks and/or assessment of new risks is necessary... 5.12.4.3. Consider the need for actions regarding combination products on the market... 5.12.4.5. Provide the results of the evaluation as an input for the review of suitability of the risk management process by top management\"",
        "Section 5.12.5: RM updates required: \"The results of any production and post-production evaluation(s) shall be recorded in the affected documents in the risk management file which include the risk management plan, hazards analysis, FMEAs, and risk management report.\"",
        "Section 5.2.12\u20135.2.14: RMP review and change records: \"The risk management plan shall be reviewed periodically... If the plan changes during the product lifecycle, a record of the changes shall be maintained in the risk management file.\"",
        "Section 5.13.1\u20135.13.3: Periodic reviews and management review: \"Periodic reviews of risk management documentation shall be conducted... The risk management process shall be reviewed as part of the management review following requirements in XX-YYY, Management Responsibility.\"",
        "Section 5.1.11: Escalation: \"Major risks shall be communicated to Senior Product Development and Quality Assurance Management.\"",
        "Figure 1 caption (visual): \"Figure 1. Risk Management Overview\" depicting iterative feedback including \"Production and post-production activities\" feeding into earlier RM phases"
      ],
      "gaps": [
        "No signal review or safety review board minutes provided to demonstrate execution of reviews.",
        "No dedicated Signal Management SOP or Safety Review Board charter included; only a reference to Post Market Surveillance and Complaint Handling Process without document ID.",
        "No evidence of actual updates made to the Hazard Analysis or Risk Management Plan (only procedural requirements).",
        "No CAPA procedure reference or CAPA records demonstrating actions taken from safety signals.",
        "No management review minutes evidencing escalation outcomes or decisions."
      ],
      "recommendations": [
        "Provide a Signal Management/Safety Surveillance SOP (or reference number to existing PMS/complaints SOP) detailing signal detection, triage, and escalation workflows aligned with ISO 14971:2019 clause 10.3.",
        "Submit recent Safety Review Board or signal review meeting minutes showing reviewed signals, decisions, and rationales.",
        "Include evidence of updates to the Risk Management File (e.g., a tracked-change Risk Management Plan revision, updated Hazard Analysis/FMEAs, and updated Risk Management Report) tied to specific post-production signals.",
        "Provide CAPA SOP reference and sample CAPA records initiated from safety signals, including linkage to RM updates and verification of effectiveness.",
        "Provide management review minutes demonstrating that results of the post-production evaluations and RM feedback were reviewed by top management, including any actions or resource decisions."
      ],
      "requirement_id": "ISO14971-10.3-01",
      "tokens_used": 17683
    },
    {
      "status": "PASS",
      "confidence": 0.86,
      "rationale": "The SOP establishes, implements, documents, and maintains an ongoing ISO 14971\u2013aligned risk management process across the full product lifecycle. It explicitly covers risk analysis, evaluation, control, residual risk evaluation, and production/post\u2011production activities, and shows integration with product realization (Design Control). A controlled procedure exists with document control, effective date, and revision history. A process flow/overview (Figure 1) shows the required elements. Cross\u2011references to related QMS processes are provided, though a few are placeholders.",
      "evidence": [
        "Cover/Header: \"Document Number: QAP013.01 ... Title: RISK MANAGEMENT PROGRAM ... Effective Date: 26Jun2024\"",
        "Section 7, Revision History: \"REV Change Summary A New Document\"",
        "Section 1.1, Purpose: \"establish, implement, document and maintain an ongoing process for risk management ... identifying hazards ... estimating and evaluating the associated risks, controlling these risks, and monitoring the effectiveness of the controls ... in accordance with ... ISO 14971:2019\"",
        "Section 1.2, Scope: \"applies ... throughout the product lifecycle phases, including product development, technology and design transfer, manufacturing, product surveillance and product discontinuation\"",
        "Section 5.1.2: \"Risk management is integrated within QAP012, Design Control as part of product realization.\"",
        "Section 5.1.4: \"The risk management process includes the following elements throughout the product life cycle: ... Identifying hazards and hazardous situations ... Estimating and evaluating the associated risks ... Controlling risk and monitoring the effectiveness ... Risk reviews ... Periodic review\"",
        "Section 5.1.5, Figure 1 (visual): Figure title: \"Risk Management Overview\". Boxes shown: Risk analysis \u2192 Risk evaluation \u2192 Risk control \u2192 Evaluation of overall residual risk \u2192 Production and post\u2011production activities; with surrounding elements: Risk management plan; Review of risk management plan.",
        "Section 5.2, Risk Management Plan: defines scope, responsibilities across lifecycle, risk acceptance criteria, verification/validation of controls, and production/post\u2011production data sources.",
        "Section 5.3.1\u20135.3.4: \"a risk management file shall be established and maintained throughout the product lifecycle\" with traceability to analysis, evaluation, control, and residual risk results.",
        "Section 5.6, Risk Analysis: defines process, intended use/misuse, hazards, hazardous situations, harms, sequences of events.",
        "Section 5.7, Risk Estimation: includes P1/P2, overall probability, severity, and risk index (Tables 1\u20135).",
        "Section 5.8, Risk Evaluation: compares estimated risk to acceptance criteria.",
        "Section 5.9, Risk Control: option analysis, implementation, verification, residual risk evaluation, benefit\u2011risk analysis, risks arising from controls, completeness.",
        "Section 5.10, Evaluation of Residual Risk: overall residual risk and disclosure.",
        "Section 5.11, Risk Management Report: pre\u2011release confirmation process and approvals.",
        "Section 5.12, Production and Post\u2011Production Activities: \"Information relevant to the combination product shall be actively collected and reviewed in the production and post\u2011production phases ... Post Market Surveillance and Complaint Handling Process\"",
        "Section 5.13, Periodic Reviews: annual or risk\u2011based reviews; management review of the risk management process.",
        "Section 5.3.5: \"controlled and maintained in the document management system in accordance with QAP001, Format, Content, Approval and Issuance of Controlled Documents.\"",
        "Section 5.5 and 5.1.2: references to QAP012, Design Control, for verification/validation and integration with product realization.",
        "Section 5.1.6 and 5.13.3: references to Management Review process (XX\u2011YYY, Management Responsibility) for reviewing risk management outputs.",
        "Section 1.4: supplier/partner application of risk management and reference to Supplier Qualification and Management (XX\u2011XXX).",
        "Section 5.1.8: training/competence cross\u2011reference to QAP011, GMP Training Program."
      ],
      "gaps": [
        "Some QMS cross\u2011references use placeholders (e.g., XX\u2011XXX Supplier Qualification and Management; XX\u2011YYY Management Responsibility) rather than specific controlled document numbers.",
        "Reference list includes \"ISO 12971: 2020\", which appears to be a typo for ISO/TR 24971:2020 (guidance) already cited elsewhere.",
        "Figure 1 is referenced and visually present, but the provided image is partially cropped; full legibility of all labels/flow arrows is not fully verifiable from the excerpt."
      ],
      "recommendations": [
        "Replace placeholder references (XX\u2011XXX, XX\u2011YYY) with the actual controlled SOP numbers/titles to strengthen QMS integration evidence.",
        "Correct the References section to consistently cite ISO/TR 24971:2020 instead of \"ISO 12971:2020\".",
        "Ensure the full, high\u2011resolution Figure 1 is included and legible in the controlled document record to clearly depict the process flow.",
        "Optionally add explicit SOP numbers for Post Market Surveillance and Complaint Handling to improve cross\u2011reference clarity."
      ],
      "requirement_id": "ISO14971-4.1-01",
      "tokens_used": 18161
    },
    {
      "status": "FLAGGED",
      "confidence": 0.62,
      "rationale": "Partial evidence of top-management commitment is present in the SOP (policy-level commitments, assigned roles, and references to management review and training). However, required objective evidence such as actual management review minutes, resourcing decisions, org charts, resource plans, and training plans/records are not included. Defined roles are clearly documented; competence and training are referenced, but not evidenced with records.",
      "evidence": [
        "Section 2, Responsibilities: Functional Area Management \u2013 \"Assures adequate resources and support to carry out this process.\" and \"Ensures provision of adequate resources and assignment of competent personnel for risk management\"; \"Reviews suitability of the risk management process at planned intervals to ensure continuing effectiveness...\"",
        "Section 2, Responsibilities: Quality Assurance Management \u2013 \"Overall responsibility for effective execution and oversight of risk management process...\" and \"Overall responsibility for the Quality Management System (QMS), including the risk management process\"",
        "Section 5.1.6 \u2013 \"management shall regularly review the outputs of processes, products, services, and the quality system, and make improvements as needed, in accordance with the Management Review Process specified in XX-YYY, Management Responsibility.\"",
        "Section 5.1.8 \u2013 \"Persons performing risk management tasks have the knowledge and experience appropriate to the tasks... Appropriate competence and training program requirements are described in QAP011, GMP Training Program.\"",
        "Section 5.2.3.2 \u2013 \"Assignment of responsibilities and authorities for the execution of specific risk management activities throughout the product lifecycle shall include...\"",
        "Section 5.2.3.2.2 \u2013 \"Top management of Product Development, Clinical Development, Regulatory Affairs and Quality Assurance establish acceptable thresholds for residual risk acceptance within this procedure.\"",
        "Section 5.11.1.6 \u2013 \"Top management of Product Development, Clinical Development, Regulatory Affairs, and QA must approve the risk management report if the benefit risk assessment is needed to justify release of the product according to established risk thresholds.\"",
        "Section 5.13.3 \u2013 \"The risk management process shall be reviewed as part of the management review following requirements in XX-YYY, Management Responsibility.\"",
        "Section 4.28, Definitions \u2013 \"Top Management: A person or group of people who directs and controls an organization at the highest level, having the power to delegate authority and provide resources within the organization.\""
      ],
      "gaps": [
        "No management review records/minutes demonstrating actual review of risk management and resourcing decisions",
        "No organizational chart showing top-management roles and reporting lines for risk management",
        "No resource plan or documented resourcing decisions specific to risk management activities",
        "No training plan details or training/competency records for personnel performing risk management tasks",
        "No explicit evidence of assignment letters or RACI beyond procedural statements",
        "Referenced procedures (XX-YYY Management Responsibility; QAP011 GMP Training Program) not provided"
      ],
      "recommendations": [
        "Provide recent Management Review minutes or report excerpts showing review of the risk management process and any resourcing decisions (cite dates, attendees, and actions).",
        "Submit an organizational chart highlighting top management roles over Product Development, Clinical Development, Regulatory Affairs, and QA with respect to risk management.",
        "Provide a resource plan or documented resourcing decisions for risk management activities (e.g., headcount allocation, budget, or approved project resourcing).",
        "Provide the training plan (QAP011) and representative training/competency records for personnel performing risk management, showing completion and qualifications.",
        "Include an approved Risk Management Plan for a product showing named or role-based assignment of responsibilities and authorities, and evidence of top management approval where applicable.",
        "Provide job descriptions or RACI matrices that define competencies and responsibilities for risk management roles."
      ],
      "requirement_id": "ISO14971-4.2-01",
      "tokens_used": 16690
    },
    {
      "status": "FLAGGED",
      "confidence": 0.6,
      "rationale": "The SOP establishes a policy framework for how risk acceptability criteria are to be created and used, cites regulatory and standards inputs, provides guidance on overall residual risk, and indicates availability via the QMS. However, it explicitly states it does not define thresholds for acceptable risk, deferring those to product Risk Management Plans (RMPs). There is also an internal inconsistency about whether thresholds are defined within the procedure. Evidence of approved, documented risk acceptability thresholds or specific device-family principles and references within actual RMPs are not provided.",
      "evidence": [
        "Section 1.1: \"establish, implement, document and maintain an ongoing process for risk management ... in accordance with ... ISO 13485:2016, ISO 14971:2019, and taking into consideration ... ISO/TR 24971:2020.\"",
        "Section 1.3: \"This SOP does not define the threshold for acceptable risk (or risk index) since this threshold will change based on the intended use and expected benefit of using the combination product.\"",
        "Section 2 (Responsibilities) \u2013 Functional Area Management: \"Defines and documents criteria for risk acceptability in the Risk Management Procedure. This provides a framework that ensures that criteria are based upon applicable national or regional regulations and relevant International Standards and considers available information such as the general acknowledged state of the art and known stakeholder concerns.\"",
        "Section 2 (Responsibilities) \u2013 Quality Assurance: \"Defines and documents criteria for risk acceptability in the Risk Management Plan according to the process established in this SOP.\"",
        "Section 3 (References): \"21CFR820.30; ISO 14971: 2019; ISO 12971: 2020 [sic, likely ISO/TR 24971:2020]; ... ISO 62366: 2005.\"",
        "Section 5.2.3.2.2: \"Top management of Product Development, Clinical Development, Regulatory Affairs and Quality Assurance establish acceptable thresholds for residual risk acceptance within this procedure.\"",
        "Section 5.2.5: \"Categories of risk and criteria for risk acceptability, in accordance with this procedure, including criteria for accepting risks when the probability of occurrence of harm cannot be estimated. The risk acceptance criteria are based on ... (1) current standard of care; (2) potential health benefits; (3) state of the art defined in recognized consensus standards.\"",
        "Section 5.2.6: \"The evaluation method and criteria for acceptability for the overall residual risk ... shall be clearly defined and documented in the risk management plan.\"",
        "Section 5.10 (Evaluation of Residual Risk): \"the Applicant shall evaluate the overall residual risk ... using the method and the criteria for acceptability of the overall residual risk defined in the risk management plan.\"",
        "Section 5.11.1.3: \"The overall residual risk acceptability and overall benefit risk analysis have been determined.\"",
        "Table 6 (Section 5.9.4.3): Action guidance tied to risk index colors (Red/Yellow/Green), including requirements for benefit-risk analysis and labeling for significant residual risks.",
        "Section 5.3.5: \"The contents of the risk management file ... shall be controlled and maintained in the document management system...\"",
        "Section 5.2.10: \"The risk management plan may be developed for a specific product or for a family of similar products, as appropriate.\"",
        "Document header: \"Document Number: QAP013.01 ... Title: RISK MANAGEMENT PROGRAM ... Effective Date: 26Jun2024\""
      ],
      "gaps": [
        "No explicit, approved Risk Acceptability Policy document separate from the SOP is provided; the SOP itself serves as a framework but states it does not define thresholds.",
        "Internal inconsistency: Section 1.3 says the SOP does not define thresholds, while Section 5.2.3.2.2 says top management establishes thresholds within this procedure.",
        "No evidence provided of actual RMPs referencing and applying the policy or documenting product-/family-specific risk acceptability criteria and overall residual risk acceptability methods.",
        "No explicit confirmation (e.g., signatures/approvals page) of top management approval of a risk acceptability policy beyond the presence of an effective date.",
        "Limited device-family-specific principles; the SOP allows family-level RMPs but does not articulate differentiated acceptability principles by family."
      ],
      "recommendations": [
        "Resolve the inconsistency between Sections 1.3 and 5.2.3.2.2: either include organizational risk acceptability thresholds/principles within the SOP or clearly state that thresholds are defined solely in RMPs and update Section 5.2.3.2.2 accordingly.",
        "Issue or append a formal Risk Acceptability Policy section approved by top management that: (a) defines organizational principles/thresholds or a clear method to set them; (b) explicitly aligns with ISO 14971:2019, ISO/TR 24971:2020, relevant regulations, state of the art, and stakeholder concerns; and (c) provides clear guidance on overall residual risk acceptability.",
        "Provide sample or actual RMPs that reference this policy and document product-/family-specific risk acceptability criteria and the overall residual risk acceptability evaluation method.",
        "Consider adding device-family-specific principles or default thresholds where appropriate to guide consistency across similar products, while allowing justified deviations in individual RMPs.",
        "Ensure the policy/SOP includes a documented approval record by top management and is clearly accessible in the document management system."
      ],
      "requirement_id": "ISO14971-4.2-02",
      "tokens_used": 18634
    },
    {
      "status": "FAIL",
      "confidence": 0.64,
      "rationale": "The SOP defines planned, periodic reviews of the risk management process and states that decisions and actions will be documented, satisfying the procedural intent. However, there is no evidence of actual execution: no Management Review records, no action tracking outputs, and no CAPA/change control artifacts showing updates to the process or procedures. Acceptance criteria require evidence of periodic reviews with inputs/outputs and action tracking, and updates to procedures as needed; these artifacts are not present.",
      "evidence": [
        "Section 2, Responsibilities: \"Reviews suitability of the risk management process at planned intervals to ensure continuing effectiveness of the risk management process and documents any decisions and actions taken\"",
        "Section 5.1.6: \"management shall regularly review the outputs of processes, products, services, and the quality system, and make improvements as needed, in accordance with the Management Review Process specified in XX-YYY, Management Responsibility.\"",
        "Section 5.1.7: \"Documented records, including evidence of decisions and actions taken, shall be maintained to ensure and demonstrate the effective planning, operation, and control of this process.\"",
        "Section 5.12.5: \"Provide the results of the evaluation as an input for the review of suitability of the risk management process by top management, as noted in Section 5.13.3.\"",
        "Section 5.13.1: \"Periodic reviews of risk management documentation shall be conducted as a post market activity on an annual basis or as specified by the team and documented in the risk management plan... These events may be planned (i.e., ... change control, ... ) or unplanned (i.e., root cause from failure investigations, product recall).\"",
        "Section 5.13.3: \"The risk management process shall be reviewed as part of the management review following requirements in XX-YYY, Management Responsibility. At a minimum, the review shall include the following: 5.13.3.1. Risk management process 5.13.3.2. Summaries of responses for critical and high risks 5.13.3.3. Risk profile(s)\""
      ],
      "gaps": [
        "No Management Review records provided to demonstrate actual periodic review execution, inputs, outputs, or decisions/actions.",
        "No CAPA or Change Control tickets showing updates to the risk management process or related procedures based on review outcomes.",
        "No action tracking logs or evidence that identified actions from reviews were monitored to closure.",
        "Referenced procedure XX-YYY (Management Responsibility) is not included; thus, inputs/outputs of management review cannot be verified.",
        "No evidence that this SOP (QAP013.01) was updated as a result of periodic suitability/effectiveness reviews."
      ],
      "recommendations": [
        "Provide recent Management Review minutes or records showing the risk management process was reviewed, including agenda, inputs (e.g., risk profiles, summaries of high/critical risks), decisions, and assigned actions with owners and due dates.",
        "Submit CAPA or Change Control records demonstrating updates/improvements to the risk management process or SOPs resulting from the reviews.",
        "Include an action tracker or log showing follow-up and closure of actions arising from the periodic and management reviews.",
        "Attach the referenced Management Responsibility procedure (XX-YYY) or excerpts to substantiate the review process and required records.",
        "Explicitly cross-reference your CAPA and Change Control procedures in Section 5.13 to ensure process deficiencies trigger formal corrective actions and controlled document updates."
      ],
      "requirement_id": "ISO14971-4.2-03",
      "tokens_used": 17015
    },
    {
      "status": "FAIL",
      "confidence": 0.78,
      "rationale": "The SOP requires competent personnel and references a training program, but it provides no objective evidence of a training matrix, training records, CVs/experience files, or defined role-based competency profiles. Some partial elements exist (requirement to document team expertise and complete training before analysis), but the acceptance criteria explicitly call for concrete artifacts which are not present in the provided document.",
      "evidence": [
        "Section 5.1.8: \"Persons performing risk management tasks have the knowledge and experience appropriate to the tasks assigned to them... Appropriate competence and training program requirements are described in QAP011, GMP Training Program.\"",
        "Section 2, Responsibilities \u2013 Functional Area Management: \"Ensures provision of adequate resources and assignment of competent personnel for risk management\"",
        "Section 2, Responsibilities \u2013 Quality Assurance: \"Completes all required training and qualification activities prior to conducting formal risk analysis\"",
        "Section 5.6.1.5: \"Risk analyses shall be conducted with the support of a team ... Expertise provided by each team member shall be documented.\"",
        "Section 5.1.7: \"Documented records, including evidence of decisions and actions taken, shall be maintained...\""
      ],
      "gaps": [
        "No training matrix presented or referenced location for it",
        "No training records or objective evidence of completed training provided",
        "No CVs/resumes or documented experience dossiers included or referenced",
        "No role-based competency profiles or job descriptions defining competencies",
        "QAP011 (GMP Training Program) is referenced but not provided to verify matrices/records"
      ],
      "recommendations": [
        "Provide the training matrix covering risk management roles and required trainings; include links or repository references.",
        "Submit training records (e.g., LMS reports) demonstrating completed and current training for personnel performing risk management tasks.",
        "Maintain and present CVs/resumes or qualification summaries for team members involved in risk management; link these to roles.",
        "Define and document role-based competency profiles (knowledge, skills, education, experience) in job descriptions or a competency matrix, and reference them in this SOP.",
        "Augment this SOP or cross-reference to QAP011 to explicitly state where objective evidence of competence (matrices, records, CVs) is stored and how it is maintained."
      ],
      "requirement_id": "ISO14971-4.3-01",
      "tokens_used": 16514
    },
    {
      "status": "FAIL",
      "confidence": 0.78,
      "rationale": "The provided document is an SOP (Risk Management Program), not a device-specific Risk Management Plan (RMP). It does not name any device or version, nor does it include a lifecycle applicability matrix mapping plan elements to lifecycle phases. While the SOP mandates that an RMP shall identify the combination product and specify the lifecycle phases for which each plan element applies, the required RMP artifact and matrix are not present. Therefore, the acceptance criteria are not satisfied.",
      "evidence": [
        "Document Header: \"QAP013.01 Title: RISK MANAGEMENT PROGRAM\" (Page 1)",
        "Section 1.2 Scope: \"This SOP applies to the commercial and investigational (clinical) combination products ... throughout the product lifecycle phases, including product development, technology and design transfer, manufacturing, product surveillance and product discontinuation.\"",
        "Section 5.2.3.1: \"[An] RMP shall be documented and shall include ... the scope of the planned risk management activities, identifying and describing the combination product (or product family), intended use, interfaces with external systems or processes, and the lifecycle phases for which each element of the plan is applicable.\"",
        "Section 5.2.10: \"The risk management plan may be developed for a specific product or for a family of similar products, as appropriate.\"",
        "Section 5.1.5 and Figure 1: \"Figure 1 illustrates the systemic representation of the risk management process. Depending on the specific product lifecycle phase, individual elements of risk management can have varying emphasis, but always governed by a risk management plan (RMP).\""
      ],
      "gaps": [
        "No device-specific Risk Management Plan (RMP) artifact is provided.",
        "No identification of a device name and version(s) within an RMP.",
        "No matrix or table mapping RMP elements to specific lifecycle phases is included.",
        "No lifecycle applicability table in the provided document; only procedural requirements exist."
      ],
      "recommendations": [
        "Provide the device-specific Risk Management Plan (RMP) vX that explicitly names the device and version(s)/configurations in scope.",
        "Include a lifecycle applicability matrix within the RMP that maps each plan element (e.g., risk analysis, risk control, verification/validation of controls, residual risk evaluation, risk management report, production and post-production surveillance, periodic review) to the relevant lifecycle phases (development, design transfer, manufacturing, post-market surveillance, discontinuation).",
        "Ensure the RMP references the governing SOP (QAP013.01) and documents responsibilities, review timing, and data sources per Sections 5.2.3 and 5.12.",
        "File the completed RMP and lifecycle applicability matrix in the Risk Management File (per Section 5.3) and cross-reference in the DHF."
      ],
      "requirement_id": "ISO14971-4.4-01",
      "tokens_used": 16684
    },
    {
      "status": "FAIL",
      "confidence": 0.78,
      "rationale": "The SOP defines functional responsibilities and requires the Risk Management Plan (RMP) to assign responsibilities and authorities, but it does not provide a RACI chart nor named owners/approvers for each risk management activity. No product-specific RMP, RACI matrix, or signature/approval records are included. Thus, acceptance criteria requiring named owners/approvers and a RACI chart in the plan are not met.",
      "evidence": [
        "Section 2. Responsibilities: \"Quality Assurance ... Approves risk management documents and risk reduction activities\"; \"Overall responsibility for effective execution and oversight of risk management process\" (Quality Assurance; Quality Assurance Management)",
        "Section 2. Responsibilities: \"Functional Area Management ... Responsible for ensuring that the risk management process is followed within area of responsibility ... Ensures risk management policies are established and followed ... Ensures provision of adequate resources and assignment of competent personnel for risk management\"",
        "Section 2. Responsibilities: \"Clinical Development \u2022 Defines applicable harms \u2022 Assigns severity rating to harms \u2022 Participates in benefit risk analysis activity\"",
        "Section 5.2.3.2: \"Assignment of responsibilities and authorities for the execution of specific risk management activities throughout the product lifecycle shall include: 5.2.3.2.1. Identification by function or area of expertise the necessary reviewers, contributors, and personnel responsible for risk management execution throughout the product lifecycle\"",
        "Section 5.2.3.2.4: \"Risk management responsibilities may be shared with design partners, consultants, contract manufacturers or suppliers, if applicable. The risk management plan shall identify the shared risk management activities, responsible party(ies), controlling procedure(s) and controlling location(s)/documentation system(s).\"",
        "Section 5.11.1.6: \"Top management of Product Development, Clinical Development, Regulatory Affairs, and QA must approve the risk management report if the benefit risk assessment is needed to justify release of the product according to established risk thresholds.\"",
        "Section 5.3.4: The Risk Management File includes a Risk Management Plan, but no RACI or named owners are shown in this document."
      ],
      "gaps": [
        "No RACI chart present in the SOP or an attached Risk Management Plan.",
        "No named owners/approvers for each risk management activity; only functional roles are described.",
        "No product-specific Risk Management Plan included to demonstrate assignments.",
        "No signatures/approval pages for the RMP or risk management activities are provided.",
        "Visual review shows tables for risk probability/severity but no RACI or signature blocks."
      ],
      "recommendations": [
        "Provide a product-specific Risk Management Plan that includes a RACI matrix mapping each risk management activity (e.g., hazard identification, risk estimation, control implementation, residual risk evaluation, PMS inputs, periodic reviews) to Responsible, Accountable, Consulted, and Informed roles.",
        "Identify named owners and approvers by person (and title) for each activity, not just by function, within the RMP.",
        "Include formal approvals/signatures for the RMP and key risk management documents (e.g., Hazard Analysis, FMEAs, Risk Management Report) and file them in the Risk Management File.",
        "Ensure the RMP explicitly lists shared activities and responsible party(ies) for external partners, with controlling procedures and documentation systems as required by Section 5.2.3.2.4.",
        "Cross-reference the RACI to design reviews and management review to demonstrate oversight and authority per ISO 14971:2019 Clause 4.4(b)."
      ],
      "requirement_id": "ISO14971-4.4-02",
      "tokens_used": 17212
    }
  ],
  "generated_at": "2025-09-25T23:44:19.446221"
}